SHS_492321 BENW CCLG 16018

A Phase 1a/1b, Multi-center, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Pleiotropic Pathway Modifier (PPM) CC-122 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

Phase Ib
NCT01421524
Cancer, All Other
Hematologic
William Bensinger, M.D.
Celgene Corporation
Tenzin Tsomo
  • Swedish Medical Center